
Wednesday, March 24, 2021 10:26:37 AM
Back to 8

Liked By
Spread the love. Be the first to like this post!
Recent FREQ News
- Current Report Filing (8-k) • Edgar (US Regulatory) • 06/06/2023 08:07:22 PM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 05/12/2023 08:07:45 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 05/12/2023 08:05:04 PM
- Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results • Business Wire • 05/12/2023 08:01:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 05/10/2023 08:06:54 PM
- Amended Annual Report (10-k/a) • Edgar (US Regulatory) • 05/01/2023 08:17:01 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 03/29/2023 08:06:57 PM
- Annual Report (10-k) • Edgar (US Regulatory) • 03/10/2023 12:42:29 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 03/10/2023 12:36:17 PM
- Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results • Business Wire • 03/10/2023 12:30:00 PM
- Frequency Therapeutics to Participate at Upcoming March Investor Conferences • Business Wire • 02/27/2023 12:30:00 PM
- Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss • Business Wire • 02/13/2023 01:05:00 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/27/2023 09:42:38 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/27/2023 09:40:52 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/27/2023 09:40:45 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/27/2023 09:38:04 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/27/2023 09:36:38 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 01/27/2023 09:35:01 PM
- Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program • Business Wire • 12/19/2022 12:30:00 PM
- Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss • Business Wire • 12/15/2022 12:30:00 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 12/13/2022 12:33:14 PM
- Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results • Business Wire • 11/17/2022 12:30:00 PM
- Frequency Therapeutics (FREQ) Receives a Buy from Robert W. Baird • TipRanks • 11/10/2022 04:16:38 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 11/08/2022 09:13:29 PM
- Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results • Business Wire • 11/08/2022 09:05:00 PM
MRES: Institute of Biomedical Research unveils artificial intelligence (AI) powered initiatives within its CBD product range, psilocybin research, and cardiometabolic health solutions • MRES • Jun 7, 2023 10:06 AM
The Supply Crisis for Rare Earth Elements Intensifies • LICY • Jun 7, 2023 9:57 AM
ILUS has Been Invited for an Interview on the Floor of the NYSE • ILUS • Jun 7, 2023 7:19 AM
PSYC's Psychedelic Spotlight Continues Ascent as a Top-Ranking Multimedia Platform for the Psychedelics Sector • PSYC • Jun 6, 2023 8:30 AM
HealthLynked Unveils Major App Update, Enhancing Personalized Healthcare Experience • HLYK • Jun 6, 2023 8:00 AM
Swifty Global Announces Acquisition of Business-to-Business Contracts and Technology from GLNetworks Ltd in Five Countries • DRCR • Jun 5, 2023 10:14 AM